Physician profile
Susan Ratay
NPI 1720333222
$378,614.81
in general payments reported to CMS, 2019-2025
55 companies · $165K in 2025
The $165K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,902 · 2020: $22K · 2021: $35K · 2022: $25K · 2023: $13K · 2024: $117K · 2025: $165K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $274K · Food and Beverage: $15K · Travel and Lodging: $5,698 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $273,521.69 |
| Food and Beverage | $14,998.54 |
| Travel and Lodging | $5,698.08 |
| Education | $258.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $208,379.29 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $161,286.16 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $3,052.95 | 2019-2025 | |
| Lilly USA, LLC | $772.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $727.14 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $534.63 | 2022-2025 | |
| Amgen INC. | $327.94 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.18 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $244.75 | 2022-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $228.70 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $204.34 | 2020-2025 | Eliquis |
| Glaxosmithkline, LLC. | $187.93 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $177.32 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.30 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $151.24 | 2022-2024 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Ratay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.